# Alfasigma USA, Inc.

> Alfasigma USA is the American nutrition and dietary-support business of Italy's privately held Alfasigma group. Built from the former Pamlab, it develops and sells medical foods and targeted nutrition brands for depression, peripheral neuropathy, mild cognitive impairment and reproductive health, while its Shreveport operation manufactures tablets, capsules and powders, packages them, tests them and moves them through a climate-controlled fulfillment network. That combination of clinician-facing products, direct commerce and contract manufacturing gives the company an unusually long view of the path from formulation to a patient's front door.

- **Founded:** 1987
- **Headquarters:** Morristown, United States
- **Founders:** Samuel M. Camp (Co-founder of Pamlab, the predecessor business), Judith M. Camp (Co-founder of Pamlab, the predecessor business)
- **Team size:** Approximately 230 U.S. employees according to the supplied company record; the wider Alfasigma group reports about 4,000 employees globally.
- **Products:** Deplin, Metanx, Cerefolin Brain Wellness, Proxeed Plus, NeevoDHA
- **Notable:** Built a U.S. medical-food portfolio with established brands in depression, neuropathy and cognitive health., Became Alfasigma's U.S. nutrition and dietary-support platform after the 2016 acquisition of Pamlab from Nestlé Health Science., Operates the Alfasigma group's U.S. manufacturing site in Shreveport, Louisiana.

## Products & services

- **Deplin** — L-methylfolate medical-food products formulated for the distinctive nutritional requirements associated with neurotransmitter imbalances in the clinical dietary management of depression and schizophrenia; intended for use under medical supervision.
- **Metanx** — A medical food for distinctive nutritional requirements associated with endothelial dysfunction in peripheral neuropathy and diabetic ulceration; intended for use under medical supervision.
- **Cerefolin Brain Wellness** — Targeted medical nutrition for mild cognitive impairment with hyperhomocysteinemia. The current formulation replaced CerefolinNAC and is offered in direct-purchase and prescription pack sizes.
- **Proxeed Plus** — A dietary supplement containing carnitines and other nutrients to support normal sperm development and male reproductive health; Alfasigma USA is the exclusive U.S. distributor and licensee.
- **NeevoDHA** — A prenatal dietary product for people who are pregnant, planning pregnancy or lactating.
- **Brand Direct Health** — A patient-access and mail-order channel that supports ordering and fulfillment, including prescription-sized supplies for selected brands.
- **Morpho CDMO - Dietary Supplements & Medical Food (US)** — Contract development, manufacturing, testing, packaging, warehousing and fulfillment for tablets, hard capsules and powders, with bottle, blister and stick-pack formats.

## Achievements

- Built a U.S. medical-food portfolio with established brands in depression, neuropathy and cognitive health.
- Became Alfasigma's U.S. nutrition and dietary-support platform after the 2016 acquisition of Pamlab from Nestlé Health Science.
- Operates the Alfasigma group's U.S. manufacturing site in Shreveport, Louisiana.
- The Shreveport factory reached seven years without a lost-time accident in April 2023.
- Expanded its factory offer under the Morpho CDMO identity introduced at CPHI 2024.
- Supports multiple dosage and packaging formats, in-house analytical and microbial testing, stability programs, warehousing and ecommerce or EDI fulfillment.

## Latest updates

- **2026-08** — Alfasigma USA was recruiting an associate brand manager for its Morristown nutrition business and expanding specialty sales hiring.
- **2026-03** — Parent Alfasigma reported fiscal 2025 revenue of €1.8 billion and 7% like-for-like growth after adjusting for the U.S. withdrawal of Ocaliva.
- **2024-10** — Alfasigma unveiled Morpho at CPHI 2024 as the identity for its global CDMO business, including the U.S. dietary-supplement and medical-food operation.
- **2023-11** — Alfasigma completed its acquisition of Intercept Pharmaceuticals, strengthening the wider group's U.S. presence in rare and serious liver disease.
- **2023-06** — The group reported that its Shreveport factory had reached seven years without a lost-time accident in April 2023.

## Links

- Website: https://www.alfasigmausa.com/
- LinkedIn: https://www.linkedin.com/company/alfasigmausa
- Twitter/X: https://twitter.com/AlfasigmaSpa
- Instagram: https://www.instagram.com/alfasigma/
- Facebook: https://www.facebook.com/AlfasigmaSPA/

---

Profile page: https://yespress.io/alfasigma-usa-inc
Published by YesPress — https://yespress.io
Last updated: 2026-08-14